SiBone (NASDAQ:SIBN) CFO Sells $60,307.80 in Stock

SiBone (NASDAQ:SIBN) CFO Anshul Maheshwari sold 3,460 shares of the firm’s stock in a transaction on Monday, November 17th. The shares were sold at an average price of $17.43, for a total value of $60,307.80. Following the completion of the transaction, the chief financial officer owned 205,073 shares of the company’s stock, valued at approximately $3,574,422.39. This represents a 1.66% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Anshul Maheshwari also recently made the following trade(s):

• On Tuesday, November 11th, Anshul Maheshwari sold 2,601 shares of SiBone stock. The stock was sold at an average price of $18.33, for a total transaction of $47,676.33.
• On Thursday, October 2nd, Anshul Maheshwari sold 3,311 shares of SiBone stock. The shares were sold at an average price of $14.20, for a total transaction of $47,016.20.

SiBone Price Performance

NASDAQ:SIBN traded up $0.24 during mid-day trading on Wednesday, hitting $18.60. 472,223 shares of the company’s stock traded hands, compared to its average volume of 442,797. The company has a debt-to-equity ratio of 0.21, a quick ratio of 6.62 and a current ratio of 7.97. The company has a market cap of $807.05 million, a PE ratio of -36.47 and a beta of 0.81. The firm’s 50 day simple moving average is $15.40 and its 200 day simple moving average is $16.72. SiBone has a 1 year low of $11.70 and a 1 year high of $20.05.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, November 10th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.05. The company had revenue of $48.66 million for the quarter, compared to the consensus estimate of $46.67 million. SiBone had a negative net margin of 11.24% and a negative return on equity of 12.86%. SiBone has set its FY 2025 guidance at EPS. Sell-side analysts expect that SiBone will post -0.78 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on SIBN shares. Weiss Ratings reiterated a “sell (d-)” rating on shares of SiBone in a report on Wednesday, October 8th. Cantor Fitzgerald set a $25.00 price objective on SiBone and gave the company an “overweight” rating in a research report on Monday, August 11th. Truist Financial decreased their price objective on SiBone from $22.00 to $20.00 and set a “buy” rating on the stock in a research note on Wednesday, October 15th. Finally, Wall Street Zen downgraded shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $23.00.

Hedge Funds Weigh In On SiBone

Several large investors have recently added to or reduced their stakes in the business. ANTIPODES PARTNERS Ltd purchased a new stake in SiBone in the first quarter valued at approximately $34,000. State of Alaska Department of Revenue acquired a new position in shares of SiBone in the 3rd quarter valued at $39,000. State of Wyoming purchased a new stake in shares of SiBone during the 2nd quarter valued at $55,000. Virtus Advisers LLC purchased a new stake in shares of SiBone during the 1st quarter valued at $58,000. Finally, Canada Pension Plan Investment Board acquired a new stake in shares of SiBone during the 2nd quarter worth $68,000. 98.11% of the stock is currently owned by hedge funds and other institutional investors.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.